Companies · Pharmaceuticals
NORTH VANCOUVER · Pharmaceuticals
Diligence memoA one-page analyst read on China-Ground Floor Holdings X, L.P. — recommendation, valuation, rhythm, risks.→China-Ground Floor Holdings X, L.P. looks under-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
China-Ground Floor Holdings X, L.P. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
China-Ground Floor Holdings X, L.P. is one of 1613 Pharmaceuticals companies tracked from NORTH VANCOUVER. By capital raised it ranks in the long tail (ahead of 10% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.
Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seed — a round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.
Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 10% of sector peers (real $). Modeled value above 18% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #54 of 71.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Dermal Life, LLC | Pre-Seed | $1.3M | $47.3M | 2.50× |
| Armgo Pharma Inc | Pre-Seed | $1.0M | $47.3M | 2.50× |
| Third Day Healing Holdings LLC | Pre-Seed | $995K | $47.1M | 2.48× |
| Dermamedics Llc | Pre-Seed | $2.0M | $45.9M | 2.42× |
| China Yongxin Pharmaceuticals Inc. | Pre-Seed | $1.4M | $42.6M | 2.25× |
| Flex Biomedical, Inc. | Pre-Seed | $2.4M | $41.7M | 2.20× |
| Spaulding Clinical Research Llc | Pre-Seed | $1.7M | $41.2M | 2.17× |
| BioAnalytix LLC | Pre-Seed | $858K | $40.6M | 2.14× |
| SteadySleep Rx Co. | Pre-Seed | $800K | $37.8M | 2.00× |
| Primrose Therapeutics, Inc. | Pre-Seed | $753K | $35.6M | 1.88× |
| Century Labs, Inc. | Pre-Seed | $750K | $35.5M | 1.87× |
| Osteologix, Inc. | Pre-Seed | $1.8M | $35.5M | 1.87× |
| China-Ground Floor Holdings X, L.P. this company | Pre-Seed | $393K | $10.6M | 0.56× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Pre-Seed | $224K | 2012-03-09 | $1.2M | $10.6M | 90% |
| Pre-Seed | $169K | 2012-03-09 | $939K | $8.0M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| David Steele | — | 2 other | 2012-03 |
China-Ground Floor Holdings X, L.P. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| EnzymeBioSystems | Pharmaceuticals | Pre-Seed | $390K | $18.4M | same sector · same stage |
| EIP Pharma LLC | Pharmaceuticals | Pre-Seed | $400K | $18.9M | same sector · same stage |
| Genebiology, Inc. | Pharmaceuticals | Pre-Seed | $400K | $18.9M | same sector · same stage |
| Medexus Pharmaceuticals Inc. | Pharmaceuticals | Pre-Seed | $400K | $18.9M | same sector · same stage |
| Primatope Therapeutics, Inc. | Pharmaceuticals | Pre-Seed | $400K | $18.9M | same sector · same stage |
| SureGene LLC | Pharmaceuticals | Pre-Seed | $400K | $18.9M | same sector · same stage |
| Metagenomix, Inc. | Pharmaceuticals | Pre-Seed | $401K | $19.0M | same sector · same stage |
| INTRACEL HOLDINGS Corp | Pharmaceuticals | Pre-Seed | $384K | $18.2M | same sector · same stage |
See where China-Ground Floor Holdings X, L.P. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at China-Ground Floor Holdings X, L.P., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.